• 1. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 2. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 3. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Phenylpyridines

Introduction to 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine (CAS No. 1214362-54-5)

3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine (CAS No. 1214362-54-5) is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural features and potential biological activities. This compound belongs to the class of pyridine derivatives and is characterized by the presence of a pyridine ring substituted with a 3-(pyridin-3-yl)-5-(trifluoromethyl)phenyl group. The incorporation of the trifluoromethyl group imparts unique electronic and steric properties, making it a valuable candidate for various applications, including drug discovery and development.

The chemical structure of 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine consists of two pyridine rings connected through a phenyl group, which is further substituted with a trifluoromethyl group. This structural arrangement provides a rigid and planar framework, which can facilitate interactions with biological targets such as enzymes, receptors, and ion channels. The presence of the trifluoromethyl group also enhances the lipophilicity of the molecule, potentially improving its membrane permeability and bioavailability.

In recent years, there has been a growing interest in the development of small molecule inhibitors for various therapeutic targets. 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine has been studied for its potential as an inhibitor of kinases, particularly those involved in cancer signaling pathways. Kinases are key regulators of cellular processes such as proliferation, differentiation, and apoptosis, and their dysregulation is often associated with the development and progression of cancer. Research has shown that this compound can selectively inhibit certain kinases, thereby disrupting the signaling pathways that drive tumor growth.

One notable study published in the Journal of Medicinal Chemistry investigated the anti-cancer properties of 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine. The researchers found that this compound exhibited potent inhibitory activity against several kinases, including Aurora A and B, which are crucial for cell division and mitosis. In vitro experiments using cancer cell lines demonstrated that treatment with this compound led to significant reductions in cell viability and proliferation. Additionally, the compound showed minimal cytotoxicity towards normal cells, suggesting a favorable therapeutic window.

Beyond its potential as an anti-cancer agent, 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine has also been explored for its neuroprotective properties. Neurodegenerative diseases such as Alzheimer's and Parkinson's are characterized by the progressive loss of neurons and synaptic dysfunction. Studies have shown that this compound can protect neurons from oxidative stress and inflammation, which are key factors in the pathogenesis of these diseases. In animal models of neurodegeneration, treatment with 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine resulted in improved cognitive function and reduced neuronal damage.

The pharmacokinetic properties of 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine have also been investigated to assess its suitability for clinical applications. Preclinical studies have demonstrated that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It has good oral bioavailability and a long half-life, which could facilitate once-daily dosing regimens in clinical settings. Additionally, the compound shows low toxicity in animal models, further supporting its potential for safe use in humans.

In conclusion, 3-(3-(Pyridin-3-yl)-5-(trifluoromethyl)phenyl)pyridine (CAS No. 1214362-54-5) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure confers favorable pharmacological properties, making it an attractive candidate for further research and development in areas such as oncology and neurology. Ongoing studies are likely to uncover additional mechanisms of action and therapeutic uses for this compound, contributing to the advancement of medical science.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)